Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Albemarle Corporation (NYSE: ALB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Virginia-incorporated public company with common stock listed on the NYSE, Albemarle regularly submits reports that cover financial results, material agreements, governance updates and other significant events.
Among the key documents are Form 8-K current reports, where Albemarle discloses items such as quarterly earnings releases, material definitive agreements, goodwill impairment conclusions, director and officer changes, and organizational structure updates. For example, recent 8-K filings have described the company’s third quarter results, the stock purchase agreement related to the sale of a controlling stake in Ketjen’s refining catalyst solutions business, the planned sale of its interest in the Eurecat joint venture, and changes in senior leadership roles.
Investors can also use this page to locate references to Albemarle’s use of proceeds from portfolio transactions, its assessment of impairment charges, and its classification of certain businesses as held for sale. These filings help explain how Albemarle manages its lithium, bromine and catalyst-related operations within its broader financial and strategic framework.
Stock Titan enhances access to Albemarle’s filings by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly understand the implications of new 8-Ks, as well as the content of other core filings such as annual and quarterly reports, and can review disclosures related to executive arrangements and board changes without reading every line of the original text.
Albemarle Corporation held its Annual Meeting of Shareholders on May 5, 2026, where all nominated directors were elected for terms expiring at the 2027 meeting. Shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Investors also approved the Albemarle Corporation 2026 Incentive Plan, which will govern future equity awards and replaces the 2017 plan. A management proposal to amend the Articles of Incorporation to remove certain supermajority provisions related to affiliated transactions did not receive sufficient support. In addition, shareholders approved a shareholder proposal expanding their ability to call a special meeting.
Albemarle delivered sharply stronger results for the quarter ended March 31, 2026, driven by higher lithium pricing and volumes. Net sales rose 33% to $1.43 billion, while gross margin expanded to 35.1% from 14.5%.
Net income attributable to Albemarle jumped to $319.1 million, and earnings per common share moved from breakeven to $2.35. Adjusted EBITDA more than doubled to $627.5 million, led by the Energy Storage segment.
The company closed the sale of its Refining Solutions business and its 50% Eurecat S.A. stake for about $648 million in cash, recording a $95.0 million loss on the business sale and a $42.3 million gain on Eurecat. Proceeds helped reduce long-term debt from $3.19 billion to $1.88 billion.
Albemarle continued cost actions, including placing Kemerton Train 1 into care and maintenance, which drove $25.9 million of restructuring and asset write-off charges this quarter and is expected to add $80–$100 million of further costs through 2027.
Albemarle reported sharply stronger results for the first quarter ended March 31, 2026, driven by its Energy Storage business. Net sales rose to $1.43 billion, up 33% year over year, while net income attributable to Albemarle increased to $319 million from $41 million.
Diluted EPS attributable to common shareholders was $2.34, and adjusted diluted EPS was $2.95. Adjusted EBITDA reached $664 million, up 148%, with Energy Storage net sales of $891 million and adjusted EBITDA of $551 million. The company generated $346 million of operating cash flow, delivered $248 million in free cash flow, closed divestitures for $648 million of net cash proceeds, and used these portfolio and cash actions to pay down $1.3 billion of debt. Albemarle ended the quarter with about $2.7 billion in liquidity and reaffirmed 2026 outlook ranges tied to different lithium price scenarios.
Albemarle Corp reports beneficial ownership held by Vanguard Capital Management as of 03/31/2026. Vanguard Capital Management reports beneficial ownership of 8,679,152 shares of Common Stock, representing 7.37% of the class. The filer discloses sole voting power for 1,016,936 shares and sole dispositive power for 8,679,152 shares.
The filing states these holdings include securities held for Vanguard funds and managed accounts and lists affiliated Vanguard entities exercising voting or dispositive power.
Vanguard Portfolio Management reports beneficial ownership of 6,331,772 shares of Albemarle Corp common stock, equal to 5.38% of the class as reported for the period ending 03/31/2026. The filer discloses sole dispositive power over 6,331,772 shares and sole voting power over 16,395 shares. The filing states these holdings reflect securities managed across Vanguard Portfolio Management LLC and affiliated advisory/business divisions and were signed on 04/28/2026.
Albemarle Corporation reported a leadership change in its finance organization. Donald J. LaBauve Jr. has informed the company of his intent to retire as Chief Accounting Officer, effective June 1, 2026, after more than 36 years of service.
The company stated that his retirement is not the result of any dispute or disagreement with Albemarle, including on accounting practices or financial reporting, indicating this is a planned transition rather than a response to any accounting or reporting issues.
ALBEMARLE CORP director Alejandro Daniel Wolff increased his holdings through an automatic dividend reinvestment. On April 1, 2026, he acquired 25 shares of common stock as dividends were reinvested under a company program, bringing his direct ownership to 13,011 shares. This was a routine, compensation-related acquisition rather than an open-market purchase.
Albemarle Corporation filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add separate financial statements for Windfield Holdings Pty Ltd. These Windfield statements are required under Rule 3-09 of Regulation S-X and are provided as Exhibit 99.1.
Windfield was significant under Rule 3-09 for the year ended December 31, 2023, so the amendment includes unaudited consolidated financial statements for 2025 and 2024 and audited consolidated financial statements for 2023. The amendment also refreshes Part IV, Item 15 with related exhibits, including new CEO and CFO certifications and an accountants’ consent, while leaving all other disclosures from the original annual report unchanged.
Albemarle Corp Schedule 13G/A amendment shows The Vanguard Group reporting zero beneficial ownership of Common Stock after an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is dated 03/13/2026 and signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.
Albemarle Corporation entered into a third amendment to its amended and restated credit agreement on March 19, 2026. The amendment extends the facility’s maturity date to at least October 28, 2028, with a possible one-year extension under specified conditions.
The changes also remove a 0.10% interest rate adjustment applied to SOFR-based loans and limit Albemarle’s ability to request maturity extensions from two times to one. Overall, the update reshapes key terms of the company’s core bank credit facility without changing lenders or the administrative agent.